["Be right" vs. "get one's rights" : Practice-oriented recommendations from a legal viewpoint]

Area of Science:

• Medical Law
• Pharmacoeconomics
• Health Policy

Background:

• German statutory health insurance prioritizes efficiency and quality in medicinal product prescriptions.
• Off-label drug use, defined as use outside approved indications or authorization, has specific regulatory considerations.

Purpose of the Study:

• To clarify legal conditions for off-label drug use within German statutory health insurance.
• To outline recommended approaches for medical professionals to mitigate legal risks (recourse) associated with off-label prescriptions.

Main Methods:

• Analysis of legal and regulatory frameworks governing pharmaceutical prescriptions in Germany.
• Review of evidence requirements for off-label drug use, including clinical trial standards.

Main Results:

• Off-label drug use is permissible under specific conditions: a severe disease, absence of approved alternatives, and scientifically substantiated probability of treatment success.
• Clinical trials supporting off-label use should ideally be placebo-controlled, randomized, and double-blinded; lower evidence standards may apply for life-threatening conditions.
• Prudent case-by-case reasoning, particularly regarding the lack of alternatives and potential criticisms, is crucial.

Conclusions:

• Justification for off-label drug use must be thorough, even when relying on less robust scientific data.
• Medical professionals must meticulously document their rationale, addressing all potential objections to safeguard against legal repercussions.